-
公开(公告)号：EP3504214B1
公开(公告)日：2020-12-02
申请号：EP17771587.7
申请日：2017-08-25
Applicant: Novartis AG
Inventor： JAIN, Rama , KOESTER, Dennis Christofer , MANNING, James R. , MARX, Vanessa , POON, Daniel , SUTTON, James Clifford , TAFT, Benjamin R. , WAN, Lifeng , YIFRU, Aregahegn , ZHAO, Qian
IPC: C07D487/14 , A61K31/5025 , A61K31/53 , A61P31/16
-
公开(公告)号：EP3063143B1
公开(公告)日：2018-05-16
申请号：EP14800191.0
申请日：2014-10-29
Applicant: Novartis AG
Inventor： BAGDANOFF, Jeffrey T. , DING, Yu , HAN, Wooseok , HUANG, Zilin , JIANG, Qun , JIN, Jeff Xianming , KOU, Xiang , LEE, Patrick , LINDVALL, Mika , MIN, Zhongcheng , PAN, Yue , PECCHI, Sabina , PFISTER, Keith Bruce , POON, Daniel , RAUNIYAR, Vivek , WANG, Xiaojing Michael , ZHANG, Qiong , ZHOU, Jianguang , ZHU, Shejin
IPC: C07D405/14 , C07D413/14 , C07D213/73 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/04 , C07D409/04 , C07D241/20 , A61K31/4418 , A61P35/00
CPC classification number: A61K31/497 , A61K31/44 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/4965 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06 , A61K2121/00 , C07D213/73 , C07D241/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D498/04
Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
-
公开(公告)号：EP2470526B1
公开(公告)日：2014-05-28
申请号：EP10748211.9
申请日：2010-08-27
Applicant: IRM LLC , Novartis AG
Inventor： HUANG, Shenlin , JIN, Xianming , LIU, Zuosheng , POON, Daniel , TELLEW, John , WAN, Yongqin , WANG, Xing , XIE, Yongping
IPC: C07D401/14 , C07D403/04 , A61K31/506 , A61P35/00
CPC classification number: C07D403/04 , A61K9/0053 , A61K31/4184 , A61K31/506 , A61K45/06 , C07D401/14 , C07D405/14 , A61K2300/00
Abstract: The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
-
公开(公告)号：EP4139301A1
公开(公告)日：2023-03-01
申请号：EP21721039.2
申请日：2021-04-20
Applicant: Novartis AG , Katholieke Universiteit Leuven KU Leuven Research & Development , Korea Research Institute of Chemical Technology
Inventor： NEYTS, Johan , POON, Daniel , PFISTER, Keith Bruce , JUNG, Young-Sik , HAN, Soo Bong , MALPANI, Yashwardhan R. , CHAKRASALI, Prashant , BISWAS, Bishyajit Kumar , KIM, Chonsaeng , SHIN, Jin Soo , KIM, Hae Soo , LEE, Chong-Kyo
IPC: C07D405/12 , C07D307/77 , A61P31/16 , A61K31/496
-
公开(公告)号：EP3504214A1
公开(公告)日：2019-07-03
申请号：EP17771587.7
申请日：2017-08-25
Applicant: Novartis AG
Inventor： JAIN, Rama , KOESTER, Dennis Christofer , MANNING, James R. , MARX, Vanessa , POON, Daniel , SUTTON, James Clifford , TAFT, Benjamin R. , WAN, Lifeng , YIFRU, Aregahegn , ZHAO, Qian
IPC: C07D487/14 , A61K31/5025 , A61K31/53 , A61P31/16
-
公开(公告)号：EP2470528B1
公开(公告)日：2014-10-01
申请号：EP10745280.7
申请日：2010-08-26
Applicant: Novartis AG
Inventor： COSTALES, Abran Q. , HUANG, Shenlin , JIN, Jeff (Xianming) , LIU, Zuosheng , PECCHI, Sabina , POON, Daniel , TELLEW, John , ZHANG, Qiong
IPC: C07D403/04 , A61K31/506 , A61P35/00
CPC classification number: C07D403/04 , A61K31/506 , A61K45/06
-
公开(公告)号：EP4356969A3
公开(公告)日：2024-05-22
申请号：EP23217305.4
申请日：2017-08-25
Applicant: Novartis AG
Inventor： JAIN, Rama , KOESTER, Dennis Christofer , MANNING, James R. , MARX, Vanessa , POON, Daniel , SUTTON, James Clifford , TAFT, Benjamin R. , WAN, Lifeng , YIFRU, Aregahegn , ZHAO, Qian
IPC: C07D471/14 , C07D487/14 , C07D498/14 , A61K31/5025 , A61K31/53 , A61P31/14 , A61P31/16
CPC classification number: C07D471/14 , C07D487/14 , C07D498/14 , A61P31/14 , A61P31/16
Abstract: The invention provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
-
公开(公告)号：EP2897961B1
公开(公告)日：2016-10-26
申请号：EP13771007.5
申请日：2013-09-17
Applicant: Novartis AG
Inventor： DILLON, Michael, Patrick , LINDVALL, Mika , POON, Daniel , RAMURTHY, Savithri , RAUNIYAR, Vivek , SHAFER, Cynthia , SUBRAMANIAN, Sharadha , TANNER, Huw
IPC: C07D207/36 , C07D487/04 , C07D487/10 , A61K31/519 , A61K31/527 , A61P35/00
CPC classification number: C07D487/04 , A61K31/519 , A61K31/527 , A61K45/06 , C07D207/36 , C07D487/10
-
公开(公告)号：EP2585454A1
公开(公告)日：2013-05-01
申请号：EP11728247.5
申请日：2011-06-23
Applicant: Novartis AG
Inventor： MADERA, Ann Marie , POON, Daniel , SMITH, Aaron
IPC: C07D417/04 , A61K31/506 , A61P35/00
CPC classification number: A61K31/506 , A61K31/4439 , A61K45/06 , C07D413/04 , C07D417/04 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I): wherein R
1 , R
2 , R
3 , and X are as defined herein. The compounds of Formula (I) and pharmaceutical compositions thereof are useful for the treatment of cancer, and B- Raf-associated diseases.
-
公开(公告)号：EP1984350A1
公开(公告)日：2008-10-29
申请号：EP07716906.8
申请日：2007-01-22
Applicant: NOVARTIS AG
Inventor： BURGER, Matthew , NI, Zhi-jie , PECCHI, Sabina , ATALLAH, Gordana , BARTULIS, Sarah , FRAZIER, Kelly , SMITH, Aaron , VERHAGEN, Joelle , ZHANG, Yanchen , WAGMAN, Allan , NG, Simon , PFISTER, Keith , POON, Daniel , LOUIE, Alicia , PICK, Teresa , BARSANTI, Paul , IWANOWICZ, Edwin , FANTL, Wendy , HENDRICKSON, Thomas , KNAPP, Mark , MERITT, Hanne , VOLIVA, Charles , WIESMANN, Marion , XIN, Xiahua
IPC: C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12 , A61K31/506 , A61P35/00
CPC classification number: C07D401/04 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12
Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.
